Table 1.

Demographics of 92 patients with Candida auris

Category	Total n = 92 (100%)
Male	48 (52.2%)
Age group
16–35 years	20 (21.7%)
36–55 years	26 (28.3%)
56–75 years	30 (32.6%)
76–96 years	16 (17.4%)
Location in hospital
ICU	30 (32.6%)
Special care	30 (32.6%)
Ward	27 (29.3%)
Outpatient	5 (5.4%)
Diabetes mellitus	26 (28.3%)
Malignancy	17 (18.5%)
Surgery	53 (57.6%)
Abdominal	12 (13%)
Cardiothoracic	8 (8.7%)
Neurosurgery	14 (15.2%)
ENT	9 (9.8%)
Orthopedics	7 (7.6%)
Others	2 (2.17%)
ICU stay in last 30 days	41 (44.6%)
Last ICU stay duration (weeks) ≤ 2 Weeks	31 (75.6%)
HDU stay in last 30 days	62 (67.4%)
Last HDU stay duration (weeks)
≤ 2 Weeks	52 (56.5%)
Indwelling lines	81 (88.04%)
Antibiotics in last 90 days	88 (95.6%)
Antifungals in last 90 days	36 (39.1%)
Fluconazole	19 (20.7%)
Voriconazole	3 (3.3%)
Amphotericin	7 (7.6%)
> 1 Antifungal	7 (7.6%)
Prior antifungal duration (weeks)
≤ 2 Weeks	25 (27.2%)
Isolation of multi-drug resistant bacteria
Prior toC.auris (≤ 90 days)	48 (52.2%)
Coinfection with C.auris	29 (31.5%)
Infected cases	65 (70.7%)
Candidemia	38 (58.5%)
Non-candidemia	27 (41.5%)
UTI	19
Peritonitis	3
Nosocomial ventriculitis	1
Empyema	1
Surgical Site Infection	1
Otitis externa	1
Keratitis	1
Colonized cases	27 (29.3%)
Asymptomatic candiduria	21
Central line tip	4
Ear Swab	1
Oral Swab	1
Antifungal resistance (n = 63)
Fluconazole	63 (100%)
Voriconazole	18 (28.57%)
Amphotericin	5 (7.93%)
Mean hospital stay (days)	30.73
Median hospital stay (days)	25 (1–163)
Mortality	39 (42.4%)
C auris death	19 (48.7%)
14-day mortality	29 (31.5%)
Mean days in which mortality occurred (days)	12.41
Median days in which mortality occurred (days)	7 (1–69)
Clinical failure	38 (41.3%)
Microbiological failure (Candidemia)	11 (40.74%)